Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia

Catia Cilloniz
ORCID logo ,
Cristina de la Calle
,
Crsitina Dominedò
,
Carolina Garcia-Vidal
,
Celia Cardozo
,
Albert Gabarrus
,
Francesc Marco
,
Antoni Torres
ORCID logo ,
Alex Soriano
*
Version 1 : Received: 22 June 2019 / Approved: 24 June 2019 / Online: 24 June 2019 (09:02:55 CEST)

A peer-reviewed article of this Preprint also exists.

Cillóniz, C.; de la Calle, C.; Dominedò, C.; García-Vidal, C.; Cardozo, C.; Gabarrús, A.; Marco, F.; Torres, A.; Soriano, A. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia. J. Clin. Med. 2019, 8, 1150. Cillóniz, C.; de la Calle, C.; Dominedò, C.; García-Vidal, C.; Cardozo, C.; Gabarrús, A.; Marco, F.; Torres, A.; Soriano, A. Impact of Cefotaxime Non-susceptibility on the Clinical Outcomes of Bacteremic Pneumococcal Pneumonia. J. Clin. Med. 2019, 8, 1150.

Abstract

Background: We aimed to analyze the impact of cefotaxime non-susceptibility on the 30-day mortality rate in patients receiving a third-generation cephalosporin for pneumococcal bacteremic pneumonia. Methods: We conducted a retrospective observational study of prospectively collected data from the Hospital Clinic of Barcelona. All adult patients with monomicrobial bacteremic pneumonia due to Streptococcus pneumoniae and treated with a third-generation cephalosporin from January 1991 to December 2016 were included. Risk factors associated with 30-day mortality were evaluated by univariate and multivariate analyses. Results: During the study period, 721 eligible episodes were identified, and data on the susceptibility to cefotaxime was obtainable for 690 episodes. Sixty six (10%) cases were due to a cefotaxime non-susceptible strain with a 30-day mortality rate of 8%. Variables associated with 30-day mortality were age, chronic liver disease, septic shock, and the McCabe score. Infection by a cefotaxime non-susceptible S. pneumoniae did not increase the mortality rate. Conclusion: Despite the prevalence of cefotaxime non-susceptible S. pneumoniae has increased in recent years. We found no evidence to suggest that patients hospitalized with bacteremic pneumonia due to these strains had worse clinical outcomes than patients with susceptible strains.

Keywords

cefotaxime; pneumonia; bacteremia; outcomes

Subject

Medicine and Pharmacology, Pulmonary and Respiratory Medicine

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.